Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status

Pharmacological Reports

Volumn 61, Issue 5, 2009, Pages 892-898

  Nagila, Amar ^a   Permpongpaiboon, Thinnakorn ^b   Tantrarongroj, Soontharee ^c   Porapakkham, Pornwalee ^d   Chinwattana, Kultira ^d   Deakin, Sara ^e   Porntadavity, Sureerut ^c  

^a Fishtail Hospital   (Nepal)

^b Huachiew University   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d MINISTRY OF PUBLIC HEALTH   (Thailand)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Atherosclerosis; Hypercholesterolemia; Oxidative stress; Paraoxonase

Indexed keywords

ALKADIENE; ARYLDIALKYLPHOSPHATASE 1; ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PEROXIDASE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; LIPID OXIDATION; OXIDATIVE STRESS; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 70549110067     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70146-X     Document Type: Article

References (50)

1. Adkins S, Gan KN, Mody M, La Du BN: Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet, 1993, 52, 598-608. (Pubitemid 23311330)
2. Aviram M: Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol Med Today, 1999, 5, 381-386.
3. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest, 1998, 101, 1581-1590. (Pubitemid 28198486)
4. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X et al.: Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA, 2008, 299, 1265-1276.
5. Brophy VH, Hasting MD, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE: Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics, 2001, 11, 77-84.
6. Buege JA, Aust SD: Microsomal lipid oxidation. Methods Enzymol, 1978, 52, 302-310.
7. Campo S, Sardo MA, Trimarchi G, Bonaiuto M, Fontana L, Castaldo M, Bonaiuto A et al.: Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in health Sicilian octogenarians. Exp Gerontol, 2004, 39, 1089-1094.
8. Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Liamia GL, Kakaidi B, Tselepis AD et al.: Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin. Arch Med Res, 2007, 38, 403-410.
9. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE: The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet, 1996, 14, 334-336.
10. Deakin S, Guernier S, James RW: Pharmacogenetic interaction between paraoxonase-1 gene promoter polymorphism C-107T and statin. Pharmacogenet Genomics, 2007, 17, 451-457. (Pubitemid 46763390)
11. Eckerson HW, Wyte CM, La Du BN: The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet, 1983, 35, 1126-1138.
12. Flemming N, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P: Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of lifestyle factors. Clin Chem, 1997, 43, 1209-1214.
13. Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, Ruiz J: Paraoxonase polymorphism MetLeu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest, 1997, 99, 62-66. (Pubitemid 27058295)
14. Garin MC, Moren X, James RW: Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. J Lipid Res, 2006, 47, 515-520. (Pubitemid 43345592)
15. Getz GS, Reardon CA: Paraoxonase, a cardioprotective enzyme: continuing issues. Curr Opin Lipidol 2005, 15, 261-267.
16. Harangi M, Seres I, Varga Z, Emri G, Szilvassy Z, Paragh G, Remenyik E: Atorvastatin effect on high- density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur J Clin Pharmacol, 2004, 60, 685-691.
17. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE: The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet, 1993, 3, 73-76.
18. Jasinska M, Owczarek J, Orszulak-Michalak D: Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep, 2007, 59, 483-499.
19. Kosecik M, Erel O, Sevinc E, Selek S: Increased oxidative stress in children exposed to passive smoking. Int J Cardiol, 2005, 100, 61-64. (Pubitemid 40487937)
20. Kural BV, Orem C, Uydu HA, Alver A, Orem A: The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia. Coron Artery Dis, 2004, 15, 277-283. (Pubitemid 39061612)
21. Ky B, Burke A, Tsimikas S, Wolfe ML, Tadesse MG, Szapary PO, Witztum JL et al.: The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol, 2008, 51, 1653-1662 (Pubitemid 351626406)
22. Leviev I, James RW: Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol, 2000, 20, 516-521. (Pubitemid 30086111)
23. Leviev I, Negro F, James RW: Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol, 1997, 17, 2935-2939.
24. Liao JK: Beyond lipid lowering: the role of statin in vascular protection. Int J Cardiol, 2002, 86, 5-18.
25. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C et al.: Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol, 2001, 21, 1451-1457.
26. Mackness B, Durrington P, Mackness M: The paraoxonase gene family and coronary heart disease. Curr Opin Lipidol, 2002, 13, 357-362. (Pubitemid 34831938)
27. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN: Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol, 1997, 122, 265-268. (Pubitemid 27397197)
28. Mackness MI, Arrol S, Abbott C, Durrington PN: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis, 1993, 104, 129-135. (Pubitemid 24035640)
29. Mackness MI, Arrol S, Durrington PN: Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett, 1991, 286, 152-154.
30. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH: Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem, 1986, 32, 671-673. (Pubitemid 17027211)
31. Mirdamadi HZ, Sztanek F, Derdak Z, Seres I, Harangi M, Paragh G: The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br J Clin Pharmacol, 2008, 66, 366-374.
32. Mulder DJ, Haelst PL, Wobbes MH, Gans RO, Zijlstra F, May JF, Smit AJ et al.: The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress. Cardiovasc Drugs Ther, 2007, 21, 91-97. (Pubitemid 46834905)
33. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, Brennan ML et al.: Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest, 1997, 99, 2005-2019. (Pubitemid 27175949)
34. Obunike JC, Pillarisetti S, Paka L, Kako Y, Butteri MJ, Ho YY, Wagner WD et al.: The heparin-binding proteins apolipoprotein E and lipoprotein lipase enhance cellular proteoglycan production. Arterioscler Thromb Vasc Biol, 2000, 20, 111-118. (Pubitemid 30048353)
35. Ostadal B: The past, the present and the future of experimental research on myocardial ischemia and protection. Pharmacol Rep, 2009, 61, 3-12.
36. Paragh G, Törocsik D, Seres I, Harangi M, Illyés L, Balogh Z, Kovacs P: Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Curr Med Res Opin, 2004, 20, 1321-1327.
37. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN: The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics, 1996, 33, 498-507. (Pubitemid 26159866)
38. Ronald S, Keany JF: Role of oxidative modification in atherosclerosis. Physiol Res, 2004, 84, 1381-1478.
39. Rosenson RS: Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis, 2004, 173, 1-12.
40. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M: Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress studies in PON1-knockout mice. Free Radic Biol Med, 2003, 34, 774-784.
41. Sardo MA, Campo S, Bonaiuto M, Bonaiuto A, Saitta C, Trimarchi G, Castaldo M et al.: Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients. Curr Med Res Opin, 2005, 21, 777-784.
42. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW et al.: Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature, 1998, 394, 284-287.
43. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, Cheroutre H et al.: Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem, 2000, 275, 17527-17535.
44. Sugiyama M, Ohashi M, Takase H, Sato K, Ueda R, Dohi Y: Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels, 2005, 20, 133-136. (Pubitemid 41031009)
45. Sumi D, Hayashi T, Thakur NK, Jayachandran M, Asai Y, Kano H, Matsui H et al.: A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects - the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis, 2001, 155, 347-357. (Pubitemid 32209305)
46. Tamura A, Watanabe T, Nasu M: Effects of atorvastatin and pravastatin on malondialdehyde-modified ldl in hypercholesterolemic patients. Circ J, 2003, 67, 816-820 (Pubitemid 37229216)
47. Tavridou A, Manolopoulos VG: Novel molecules targeting dyslipidemia and atherosclerosis. Curr Med Chem, 2008, 5, 792-802.
48. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ et al.: Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation, 2002, 106, 484-490. (Pubitemid 34803695)
49. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M: Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest, 1995, 96, 2882-2891.
50. Yeung AC, Tsao P: Statin therapy: beyond cholesterol lowering and anti-inflammatory effects. Circulation, 2002, 105, 3017-3024.